Chronic kidney disease (CKD) is responsible for a public health burden with multi-systemic complications. Through transancestry meta-analysis of genome-wide association studies of estimated glomerular filtration rate (eGFR) and independent replication (n = 1,046,070), we identified 264 associated loci (166 new). Of these, 147 were likely to be relevant for kidney function on the basis of associations with the alternative kidney function marker blood urea nitrogen (n = 416,178). Pathway and enrichment analyses, including mouse models with renal phenotypes, support the kidney as the main target organ. A genetic risk score for lower eGFR was associated with clinically diagnosed CKD in 452,264 independent individuals. Colocalization analyses of associations with eGFR among 783,978 European-ancestry individuals and gene expression across 46 human tissues, including tubulo-interstitial and glomerular kidney compartments, identified 17 genes differentially expressed in kidney. Fine-mapping highlighted missense driver variants in 11 genes and kidney-specific regulatory variants. These results provide a comprehensive priority list of molecular targets for translational research.
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. Its associated burden of disease encompasses metabolic disturbances, end-stage kidney disease and multi-systemic complications such as cardiovascular disease [1] [2] [3] [4] . CKD is a leading cause of death 5 and has shown one of the highest increases in disease-attributable mortality over the last decade 2 . Nevertheless, public and clinical awareness remain low 3 . Moreover, clinical trials in nephrology are still under-represented 6 , which has resulted in a scarcity of therapeutic options to alter disease progression and high costs for health systems 7 . A major barrier to developing new therapeutics is the limited understanding of the mechanisms underlying kidney function in health and disease, with the consequent lack of therapeutic targets.
Genome-wide association studies (GWAS) and exome-chip studies of the glomerular filtration rate estimated from serum creatinine (eGFR), the main biomarker to quantify kidney function and define CKD, have identified nearly 100 eGFR-associated genetic loci 8 in samples of European [9] [10] [11] [12] [13] [14] [15] , Asian [16] [17] [18] [19] and multiple 20 ancestry. However, similarly to other complex traits and diseases, identifying causal genes and molecular mechanisms implicated by genetic associations is challenging and has only been successful for a few kidney-function-associated loci 21, 22 . Advanced statistical fine-mapping approaches and newly emerging multi-tissue gene expression data provide new opportunities for prioritizing putative causal variants, effector genes and target tissues from the results of large-scale GWAS meta-analyses.
We therefore conducted a trans-ancestry GWAS meta-analysis in the CKD Genetics (CKDGen) Consortium (n = 765,348) and replicated findings in the Million Veteran Program (MVP; n = 280,722) 23 , for a combined sample size of greater than 1 million participants. The first aim of this study was to identify new globally important loci for kidney function through maximizing statistical power ( Supplementary Fig. 1 ). Results from GWAS of the complementary kidney function marker blood urea nitrogen (BUN; n = 416,178) were used to prioritize the eGFR-associated loci on the basis of those most likely to be relevant for kidney function. A genetic risk score (GRS) for low eGFR was used to test relevance for clinically diagnosed CKD among 452,264 independent individuals. The second aim was to characterize replicated eGFR-associated loci through complementary computational approaches, including various enrichment and network analyses, fine-mapping, and colocalization with gene expression in 46 tissues and protein levels ( Supplementary Fig. 1 ). We focused this aim on European-ancestry individuals, as fine-mapping based on summary statistics requires linkage disequilibrium (LD) reference panels whose sample size scales with that of the GWAS 24 . The resulting list of prioritized variants and genes provides a rich resource of potential therapeutic targets to improve CKD treatment and prevention.
Genetic correlations of eGFR and BUN with other phenotypes.
We assessed genome-wide genetic correlations (r g ) of eGFR associations with each of 748 complex traits and diseases (Methods) 28 . We observed 37 significant correlations (P < 6.7 × 10 −5 = 0.05/748; Supplementary Fig. 6 and Supplementary Table 7) . After serum creatinine, the largest negative correlations were observed between eGFR and serum citrate (r g = −0.27) and urate (r g = −0.23), followed by anthropometric traits including lean mass and physical fitness (for example, r g = −0.20 for left hand grip strength). While the inverse correlation with muscle-mass-related traits probably reflects higher creatinine generation leading to lower creatininebased eGFR, the correlations with citrate and urate levels probably reflect reduced filtration function, as does the positive correlation with GFR estimated from cystatin C (r g = 0.53).
A very similar pattern of genetic correlations was observed for BUN (Supplementary Table 7 ), but the genetic correlations with muscle-mass-related traits were generally lower than for eGFR. The largest genetic correlation for BUN was observed with CKD (r g = 0.47), as compared to creatinine-based (r g = −0.29) and cystatin C-based (r g = −0.26) eGFR.
In summary, significant genetic correlations with eGFR reflect the two biological components that govern serum creatinine concentrations: its excretion via the kidney and its generation in muscle. The fact that genetic correlations between BUN and muscle-mass-related traits are generally lower than was observed for eGFR underscores the value of using genetic associations with BUN to help prioritize eGFR-associated loci most likely to be relevant for kidney function.
Functional enrichment and pathway analyses.
To identify molecular mechanisms and tissues of importance for kidney function, we assessed the enrichment of the eGFR and BUN genetic associations by using tissue-specific gene expression, regulatory annotations, and gene sets and pathways (Methods). First, we used eGFR-associated SNPs (P < 5 × 10 We identified 16 significantly enriched physiological systems, cell types and tissues highlighting several aspects of kidney function, physiology and disease. The strongest enrichment was observed for urogenital and renal physiological systems and tissues (kidney, kidney cortex and urinary tract; false-discovery rate (FDR) < 0.05; Supplementary Fig. 7a,b ). Pathway and gene set enrichment analysis identified three highly correlated and strongly associated meta gene sets (P < 1 × 10
, FDR < 0.05), including some relevant to the kidney such as polyuria, dilated renal tubules and expanded mesangial matrix, as well as signaling and transcription, and energy metabolism ( Supplementary Fig. 7c ). Tissue and cell-type enrichment analysis of BUN-associated SNPs associated at P < 5 × 10 −8 highlighted a very similar pattern ( Supplementary Fig. 8 ) but without enrichment for muscle tissues, further supporting the use of BUN to prioritize the loci most likely to be related to kidney function.
Second, we used stratified LD score regression 30 on the genomewide eGFR and BUN summary statistics to identify cell-type groups with enriched heritability on the basis of data from diverse cell-type-specific functional genomic elements. The strongest enrichment for eGFR was observed for the kidney (13.2-fold), followed by the liver (7.3-fold) and adrenal/pancreas (5.7-fold enrichment; Supplementary Table 8 ). The kidney was also the most enriched cell-type group for BUN (11.5-fold enrichment; Supplementary Table 8) .
Finally, by using a complementary approach, we assessed enrichment of eGFR-associated variants in genes in which disruption results in kidney phenotypes in genetically manipulated mice 31 . From the Mouse Genome Informatics (MGI) database, we selected all genes for which disruption causes abnormal GFR (n = 24), abnormal kidney physiology (n = 453) or abnormal kidney morphology (n = 764) and interrogated their human orthologs in the eGFR summary statistics (Methods). We identified significant associations in ten genes linked to abnormal GFR in mice (enrichment P = 8.9 × 10 −4 ), 55 linked to abnormal kidney physiology
) and 96 linked to abnormal kidney morphology (enrichment P = 1.8 × 10 ; Fig. 3 and Methods). Of these, 25 genes represent new eGFR candidate genes in humans; that is, they have not previously been reported to contain genomewide-significant eGFR-associated SNPs or map near known loci (Supplementary Table 9 ). The existing mouse models may pave the way for experimental confirmation of these findings. restricted to European-ancestry participants, for whom data to construct a large enough LD reference panel were publicly available (Methods). Meta-analysis of 85 European-ancestry CKDGen GWAS identified 256 genome-wide-significant loci (Supplementary the remaining 7 showed P ≤ 3.3 × 10 −6 in the trans-ancestry discovery analysis. BUN GWAS meta-analysis of CKDGen Europeanancestry studies (n = 243,029) allowed us to classify 122 SNPs as likely relevant for kidney function, 90 as inconclusive and 16 as unlikely (Supplementary Table 10 ).
To conduct statistical fine-mapping of the 228 eGFR loci, we first performed summary-statistics-based conditional analysis and identified 253 independent genome-wide-significant SNPs (Supplementary  Table 11 ) mapping to 189 regions (Methods). For each independent variant, we computed a 99% credible set 32 , with a median set size of 26 SNPs (IQR: 6, 60). We observed 58 small credible sets (≤5 SNPs), including 20 single-SNP sets: EDEM3, CACNA1S, HOXD11, CPS1, DAB2, SLC34A1, LINC01512, LARP4B, DCDC1, SLC25A45, SLC6A13, GATM, CGNL1, CYP1A1, NRG4, RPL3L, UMOD-PDILT, SLC47A1 and two independent sets at BCL2L14 (Fig. 4 and Supplementary Table 11 ). Of the 58 small credible sets, 33 were likely relevant for kidney function and contain genes and SNPs that can now be prioritized for further study (Supplementary Table 11 ). CYP19A1  SALL1  NFIA  PKN1  LAMC1  KLF3  CLDN10  PIGV  ASL  MAS1  SLC2A9  STK36  CA2  SLC3A1  ACP2  QRICH1  TCF21  ACTN4  LAMB2  C4A  C4B  PSPH  BMP7  CASR  BMP4  NPHS1  TOM1L2  GRK6  MXI1 ), and the solid gray line corresponds to the experiment-wide significance threshold for each nested candidate gene analysis. Orange, genome-wide significance; red, experiment-wide but not genome-wide significance; blue, no significantly associated SNPs. Genes are labeled if they reached experiment-but not genome-wide significance; black font indicates genes not mapping to loci reported in the main analysis. Enrichment P values correspond to the observed number of genes with association signals below the experiment-wide threshold against the number expected on the basis of the complementary cumulative binomial distribution (Methods). 
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Credible set SNPs were annotated with respect to their functional consequence and regulatory potential. Missense SNPs with >50% posterior probability (PP) of driving the association and/or mapping to a small credible set are of particular interest because they directly implicate the affected gene. Such missense SNPs were identified in 11 genes (SLC47A1, RPL3L, SLC25A45, CACNA1S, EDEM3, CPS1, KLHDC7A, PPM1J, CERS2, C9 and SLC22A2; Supplementary Table 12) , of which CACNA1S, RPL3L, CERS2 and C9 were likely relevant for kidney function (Fig. 4a) . The majority of the 11 variants had a combined annotation-dependent depletion (CADD) score greater than 15, indicating potential deleteriousness 33 . Several identified genes are plausible biological candidates for driving the association signal (Table 1) . For example, the missense p.(Ala465Val) SNP in SLC47A1 (PP > 99%) alters the encoded multidrug and toxin extrusion protein (MATE1), a transport protein responsible for the secretion of cationic drugs, toxins and internal metabolites including creatinine across brush border membranes, including kidney-proximal tubules. The fact that Slc47a1-knockout mice have higher blood levels of both creatinine and BUN 34 argues against a sole effect on creatinine transport.
To evaluate the regulatory potential of SNPs from small credible sets in the kidney, we annotated them to open chromatin regions identified from primary human tubular and glomerular cell cultures 35 , as well as from publicly available kidney cell types (Methods). We identified 72 SNPs mapping to one of these annotations, which may thus represent causal regulatory variants (Supplementary Table 12 ). A particularly interesting finding was the intronic rs77924615 SNP in PDILT, which showed PP > 99% of driving the association at the UMOD locus and mapped to open chromatin in all evaluated resources (native kidney cells, ENCODE and Roadmap kidney cell types; Fig. 4b ).
Gene prioritization: colocalization with gene expression. We performed colocalization analyses for each eGFR-associated locus with gene expression in cis across 46 tissues, including kidney glomerular and tubulo-interstitial compartments (Methods). PP > 80% of colocalization in at least one kidney tissue was observed for 17 transcripts mapping to 16 of the 228 replicated loci (Fig. 5) , pointing toward a shared underlying SNP associated with both eGFR and gene expression and implicating the gene encoding the colocalized transcript as the effector gene for the locus.
New insights emerged on several levels: first, UMOD is a wellestablished causal gene for CKD and can therefore be used to evaluate our workflow. In the tubulo-interstitial compartment, we observed a shared underlying variant associated with higher UMOD gene expression and lower eGFR (Fig. 5 ), in agreement with previous GWAS of urinary uromodulin concentration, in which alleles associated with lower eGFR at UMOD 15 were associated with higher urinary uromodulin concentrations 36 . The lead SNP at this locus was rs77924615, highlighted above as the candidate causal regulatory variant mapping to an intron of PDILT (upstream of UMOD). The association with differential UMOD but not PDILT gene expression supports UMOD as the causal gene and rs77924615 as a regulatory SNP. , indicating that this transporter is essential in excreting toxins. The locus has been reported in previous GWAS of eGFR 13 .
Genes are included if they contain a missense SNP with a PP of association of >50% or map to a small credible set (≤5 SNPs). PP, posterior probability; CADD score, combined annotation-dependent depletion (CADD) Phred-like score (Methods); DHSs, DNase I-hypersensitive sites. a Boldface indicates the SNPs most likely to be relevant for kidney function on the basis of combined effects on eGFR and BUN.
Table 1 | Genes implicated as causal via identification of missense sNPs with high probability of driving the eGFR association signal (continued)
Second, new biologically plausible candidates emerged. For example, our results suggest KNG1 and FGF5 as effector genes in the respective eGFR-associated loci ( Fig. 5 and Supplementary  Table 13 ). KNG1 encodes the high-molecular-weight kininogen, which is cleaved to bradykinin. Bradykinin influences blood pressure, natriuresis and diuresis and can be linked to kidney function via the renin-angiotensin-aldosterone system 37 . FGF5 encodes fibroblast growth factor 5, and the index SNPs for eGFR or highly correlated SNPs (r 2 > 0.9) have been identified in multiple GWAS of blood pressure, atrial fibrillation, coronary artery disease, hematocrit and multiple kidney-function-related traits (Supplementary Table 13 ). The eGFR index SNP rs1458038 (PP > 50%, CADD score = 14.8; Supplementary Table 13) colocalized with the eGFR signal only in the tubulo-interstitial kidney portion (Fig. 5) , supporting its regulatory potential in controlling the expression levels of FGF5 in this compartment. Both KNG1 and FGF5 index SNPs were associated with BUN and CKD and are thus probably related to kidney function.
Third, for loci that showed colocalization of eGFR signals with gene expression in kidney and multiple other tissues, in some cases the allelic effect direction on gene expression was concordant across all tissues (for example, METTL10), whereas in other cases it differed by tissue (for example, SH3YL1; Fig. 5 ). These observations were also reflected broadly across all transcripts with evidence of colocalization in any tissue ( Supplementary Fig. 9 ) and highlight tissue-shared and tissue-specific signals 38, 39 . Finally, trans expression quantitative trait locus (trans-eQTL) annotation of the index SNPs in whole and peripheral blood identified a reproducible link of rs10774625 (12q24.11) with several transcripts (Methods , Supplementary Tables 14 and 15 , and Supplementary Note 2).
Colocalization with uromodulin protein levels in urine.
The UMOD locus is of particular clinical interest for CKD research 21 : rare UMOD mutations cause autosomal dominant tubulo-interstitial kidney disease 40 , and common variants at UMOD give rise to the strongest eGFR and CKD GWAS signals 15 . We therefore performed conditional analyses based on European-ancestry-specific summary statistics and found two independent variants: rs77924615, mapping upstream of PDILT, and rs34882080, mapping to an intron of UMOD (Fig. 6a) . SNP association with the urinary uromodulinto-creatinine ratio (UUCR) in one participating cohort (Fig. 6b) matched the eGFR association pattern. Colocalization of the conditional eGFR and UUCR associations was evaluated separately for rs34882080 (Fig. 6c) and rs77924615 (Fig. 6d) . Both regions showed high probability of a shared underlying variant driving the respective associations with eGFR and UUCR levels (PP = 97% and 96%, respectively), further supporting rs77924615 as a causal regulatory variant and UMOD as its effector gene.
A summary of the various gene characterization results for replicated loci from the European-ancestry analysis is shown in Supplementary Table 16 , to facilitate selection of the most promising candidates for further experimental studies.
Discussion
This trans-ancestry study is fivefold larger than previous GWAS meta-analyses for eGFR and identified 264 replicated loci, 166 of which are reported here for the first time. By also analyzing BUN, an established complementary marker of kidney function, we highlight eGFR-associated loci that are likely to be important for kidney function as opposed to creatinine metabolism and provide a comprehensive annotation resource. Clinical relevance is supported by associations of a GRS for low eGFR with higher odds of
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UMOD, rs77924615 clinically diagnosed CKD, CKD-related phenotypes and hypertension. Enrichment analyses confirm the kidney as the main target organ. Colocalization of associations with eGFR and gene expression in the kidney implicates specific target genes for follow-up. Conditional analyses, fine-mapping and functional annotation at 228 replicated eGFR-associated loci among European-ancestry participants implicate single potentially causal variants at 20 loci. Most previous GWAS meta-analyses for eGFR have been limited to a single ancestry group 8 and did not prioritize causal variants or effector genes in associated loci. Although underpowered to uncover new loci, one previous trans-ancestry study used finemapping, resolving one signal to a single variant 20 , rs77924615 at UMOD-PDILT, which is also identified in our study. At this locus, we further characterized the relationship between the causal variant, UMOD expression in the target tissue and uromodulin protein levels. This increase in resolution-from a locus to a single potentially causal variant with its effector gene, protein and target tissuerepresents a critical advance over 10 years of eGFR GWAS 15 and is a prerequisite for translational research.
The complementary multi-tissue approaches, including enrichment analyses based on gene expression, regulatory annotations, and gene sets and pathways, highlight the kidney as the most important target organ. However, relatively few kidney-specific experimental datasets are publicly available. For example, the kidney is not well represented in the Genotype-Tissue Expression (GTEx) Project and is not included in its tissue-specific eQTL datasets 38 , emphasizing the value of open-access resources and in-depth characterization of uncommon tissues and cell types. We were able to specifically investigate the kidney by using a recently published eQTL dataset from glomerular and tubulo-interstitial portions of microdissected human kidney biopsies 41 , kidney-specific regulatory information from the ENCODE and Roadmap Epigenomics resources, and by obtaining regulatory information from primary cultures of human glomerular and tubulo-interstitial cells resolution or at a resolution of ≤5 SNPs, some of which may have broader clinical relevance. For example, the OCT2 protein encoded by SLC22A2 transports several cationic drugs such as metoprolol, cisplatin, metformin and cimetidine across the basolateral membrane of renal tubular cells 42 . The prioritized missense SNP encodes p.(Ser270Ala), a known pharmacogenomic variant that alters the transport of these drugs and their side effects, such as cisplatininduced nephrotoxicity 43 . Along the same lines, the prioritized SNP encoding the p.(Ala465Val) substitution in the transporter MATE1 encoded by SLC47A1 may affect the ability to secrete drugs and other toxins from proximal tubular cells into the urine 44 and hence alter CKD risk.
Strengths of this project include the large sample size with dense genotype imputation, standardized and automated phenotype generation and quality control, and independent replication, as well as the advanced and comprehensive downstream bioinformatics analyses. Further strengths are the use of BUN to prioritize eGFRassociated loci likely relevant for kidney function and to provide genome-wide BUN summary statistics as an annotation resource for other studies of eGFR. Moreover, we evaluated a GRS for eGFR for association with clinically diagnosed CKD in a large independent study. Among the limitations, non-European populations are still under-represented in our study, as in many other genomic efforts 45 . Statistical fine-mapping using trans-ancestry data with different LD structures can potentially narrow association signals. However, a sufficiently large reference dataset to compute ancestry-matched LD structure for summary-statistics-based fine-mapping was only available for European ancestry, highlighting the potential of future large-scale efforts with trans-ancestry fine-mapping and the need to generate data from non-European-ancestry populations, thereby enabling such endeavors. Finally, several SNPs had small effective sample sizes in some subpopulations, which might have affected the ability to assess between-ancestry heterogeneity and potentially underestimated true heterogeneity.
We estimated GFR from serum creatinine, as done in clinical practice and observational studies, because direct measurement of kidney function is invasive, time-consuming and burdensome. Under the assumption that genetic associations supported by multiple markers are less likely to reflect marker metabolism, we used BUN to prioritize eGFR-associated loci likely to be relevant to kidney function. Blood creatinine, urea and cystatin C concentrations are influenced not only by glomerular filtration but also by the synthesis, active secretion and reabsorption of these molecules, as illustrated by loci detected in our study: for example, the GATM locus was associated with eGFR but not with BUN, in agreement with the function of the encoded protein as a rate-limiting enzyme in creatine synthesis 46 . Conversely, the SLC14A2 locus was associated with BUN but not with eGFR, in line with the function of the encoded protein as a urea transporter 47 . Even so, lack of association for a SNP with one kidney function marker based on a combination of P value and effect direction may not necessarily mean that the locus is not relevant to kidney function. Our categorization of the eGFR loci into three classes on the basis of direction of effect and significance of BUN association should be interpreted with caution, with 'likely' and 'unlikely' reflecting uncertainty of the assignment. Factors complicating the comparison of eGFR and BUN associations at the locus level are differential statistical power, differential ancestry distribution and potential allelic heterogeneity. Further large-scale studies with multiple kidney function markers measured in the same individuals are therefore warranted.
To identify broadly representative and generalizable association signals, we focused on SNPs that were present in the majority of the participating studies. This choice might have limited our ability to uncover new variants or to fine-map low-frequency or population-specific variants, which represents a complementary avenue of research. Moreover, even with well-powered fine-mapping approaches, potentially causal SNPs need to be confirmed as functional variants in experimental studies. Although colocalization with gene expression can help prioritize effector genes, these associations are based on measures from a single time point and hence cannot answer whether changes in gene expression precede or follow changes in kidney function.
In summary, we have identified and characterized a large number of loci associated with eGFR and prioritized potential effector genes, driver variants and target tissues. These findings will help direct functional studies and advance the understanding of kidney function biology, a prerequisite to develop novel therapies to reduce the burden of CKD.
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Data collection
To maximize phenotype standardization across studies, an analysis plan and a command line script (https://github.com/genepi-freiburg/ ckdgen-pheno) were created centrally and provided to all participating studies. Data processing, analysis and troubleshooting instructions were distributed to all studies via a Wiki system (https://ckdgen.eurac.edu/mediawiki/index.php/ CKDGen_Round_4_EPACTS_analysis_plan). Automatically generated summary files were checked centrally. Upon phenotype approval, studies run their GWAS and uploaded results and imputation quality (IQ) information to a common calculation server. GWAS QC was performed using GWAtoolbox and custom (R, Bash) scripts to assess ancestry-matched allele frequencies and variant positions. Table 2 for study-specific genotyping arrays, haplotype phasing and genotype imputation methods. Fixed effects inverse-variance weighted meta-analysis was performed using METAL (version 2011-03-25), which was adapted to increase the precision of effect estimates and their standard errors (SE; seven decimal places instead of four). We evaluated ancestry-related heterogeneity using the software Meta-Regression of Multi-Ethnic Genetic Association (MR-MEGA v0.1.2). Genetic heritability was estimated using the R package 'MCMCglmm'. We estimated pairwise genetic correlation coefficients through LD Hub v1.9.0 using LD Score regression. We used DEPICT v1 release 194 to perform Data-Driven Expression Prioritized Integration for Complex Traits analysis. A nested candidate gene analysis was performed using GenToS (https://github.com/genepi-freiburg/GenToS). Approximate conditional analyses were conducted using the GCTA v1.91.6beta COJO-Cond and -Slct algorithms. Using the Wakefield's formula implemented in the R package 'gtx', we derived approximate Bayes factors (ABF). Functional annotation of SNPs mapping into credible sets was performed with SNiPA v3.2 (March 2017), based on the 1000Gp3v5 and Ensembl v87 datasets. SNiPA was also used to derive the Combined Annotation Dependent Depletion (CADD) PHRED-like score, based on CADD v1.3. The Ensembl VEP tool was used for SNP's primary effect prediction. For co-localization analyses, we used the 'coloc.fast' function from the R package 'gtx' (https://github.com/tobyjohnson/gtx), which is an adaption of Giambartolomei's co-localization method.
Data analysis See Supplementary
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
nature research | reporting summary
October 2018
Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Genome-wide summary statistics for this study are made publicly available through dbGaP accession number phs000930.v7.p1 and at http://ckdgen.imbi.unifreiburg.de.
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Sample size
Studies contributed 121 GWAS summary statistics files for eGFR (total post-QC n=765,348), 60 GWAS files for CKD (total post-QC n=625,219, including 64,164 CKD cases), and 65 GWAS files for BUN (total post-QC n=416,178).
Data exclusions Before meta-analysis, study-specific GWAS files were filtered to retain only variants with IQ score>0.6 and minor allele count (MAC)>10. After meta-analysis of 43,994,957 SNPs, only SNPs present in ≥50% of the GWAS files and with total MAC≥400 were retained. Across ancestries, this yielded 8,221,591 variants for eGFR (8, 834 ,748 in EA), 8,176,554 for BUN (8, 358 ,347 in EA), and 9,585,923 for CKD.
